OncoCyte Operating Margin from 2010 to 2025

OCX Stock  USD 2.58  0.06  2.38%   
OncoCyte Corp Operating Profit Margin yearly trend continues to be fairly stable with very little volatility. Operating Profit Margin will likely drop to -15.8 in 2025.
Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 56.8 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 13.9, Dividend Yield of 0.0015 or PTB Ratio of 0.64. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.
  
Check out the analysis of OncoCyte Corp Correlation against competitors.
For more information on how to buy OncoCyte Stock please use our How to Invest in OncoCyte Corp guide.

Latest OncoCyte Corp's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of OncoCyte Corp over the last few years. It is OncoCyte Corp's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OncoCyte Corp's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (55.43) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

OncoCyte Operating Margin Regression Statistics

Arithmetic Mean(21.33)
Geometric Mean20.31
Coefficient Of Variation(25.29)
Mean Deviation4.27
Median(24.43)
Standard Deviation5.39
Sample Variance29.09
Range18.3578
R-Value0.67
Mean Square Error17.20
R-Squared0.45
Significance0
Slope0.76
Total Sum of Squares436.35

OncoCyte Operating Margin History

2025 -15.8
2024 -15.05
2023 -16.72
2022 -18.79
2021 -6.08

About OncoCyte Corp Financial Statements

OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. Oncocyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for OncoCyte Stock Analysis

When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.